Skip to content

AFS Securities at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$67.48M+194%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$54M+575%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$630.67M-7.4%
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$820.38M+22.0%
Replimune Group logo
Replimune GroupREPL
$0

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.4%
Enterprise value$923.07M+23.9%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s AFS securities?
Oric Pharmaceuticals, Inc. (ORIC) reported AFS securities of $137.78M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s AFS securities changed year-over-year?
Oric Pharmaceuticals, Inc.'s AFS securities increased by 587.6% year-over-year, from $20.04M to $137.78M.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.